中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (4): 274-277.doi: 10.12144/zgmfskin202604274

• 临床研究 • 上一篇    下一篇

乌帕替尼成功治疗青斑样血管病三例

谢画1,2,卢方麟2,赵莎2,王小康2,陈菲菲2,朱晓芳1,2   

  1. 1扬州大学附属苏北人民医院，江苏扬州，225001； 2江苏省苏北人民医院，江苏扬州，225001
  • 出版日期:2026-04-15 发布日期:2026-04-07

Three cases of livedoid vasculopathy successfully treated with upadacitinib

XIE Hua1,2, LU Fanglin2, ZHAO Sha2, WANG Xiaokang2, CHEN Feifei2, ZHU Xiaofang1,2   

  1. 1 Department of Dermatology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou 225001, China; 2 Department of Dermatology, Northern Jiangsu People's Hospital, Yangzhou 225001, China
  • Online:2026-04-15 Published:2026-04-07

PDF (PC)

6

摘要： 本文报道3例接受乌帕替尼治疗的青斑样血管病患者，均取得良好疗效。患者1，女，46岁，给予乌帕替尼缓释片15 mg每日1次，4周后皮疹显著好转，疼痛明显缓解；患者2，女，15岁，给予乌帕替尼缓释片15 mg每日1次，8周后皮损显著改善，调整为15 mg隔日1次继续口服16周，停药半年后随访未见复发；患者3，男，15岁，给予乌帕替尼缓释片15 mg每日1次治疗，4周后瘀斑消退，随访32周，皮疹控制良好无复发。3例患者治疗期间均未见不良反应。

关键词: 乌帕替尼, 青斑样血管病, 治疗, JAK抑制剂

Abstract: Three patients with livedoid vasculopathy who received upadacitinib treatment were reported herein, all of whom achieved good curative effects. Patient 1 was a 46-year-old female who was given 15 mg of upadacitinib sustained-release tablets once daily; significant improvement of skin rashes and obvious relief of pain were observed after 4 weeks. Patient 2 was a 15-year-old female who was administered 15 mg of upadacitinib sustained-release tablets once daily; the skin lesions improved significantly after 8 weeks, and the dosage was adjusted to 15 mg every other day for continuous oral administration for 16 weeks, with no recurrence found during follow-up half a year after drug withdrawal. Patient 3 was a 15-year-old male who received 15 mg of upadacitinib sustained-release tablets once daily; ecchymoses subsided after 4 weeks, and during 32 weeks of follow-up, the skin rashes were well-controlled without recurrence. No adverse reactions were observed in the three patients during the treatment period.

Key words: upadacitinib, livedoid vasculopathy, treatment, JAK inhibitor